country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

製品番号: HY-11088

Copy Link Print Information

PF-3052334

PF-3052334 is an orally active, hepatically selective HMG-CoA reductase inhibitor with an IC₅₀ of 1.9 nM. PF-3052334 inhibits cholesterol synthesis, with IC₅₀ values of 0.9 and 730 nM in hepatocytes and muscle cells, respectively. PF-3052334 can be used to study hypercholesterolemia.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号: 887702-61-6
分子式: C₂₈H₃₃FN₃NaO₅
分子量:533.57

保管条件:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (271 KB)

PF-3052334 構造式

CAS 番号: 887702-61-6

価格（税別）

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

Cellular Effect

Cell Line	Type	Value	Description	References
Hepatocyte	IC₅₀	0.9 nM Compound: 35, PF-3052334	Inhibition of cholesterol synthesis in rat hepatocytes Inhibition of cholesterol synthesis in rat hepatocytes	[PMID: 18072721]
L6	IC₅₀	730 nM Compound: 35, PF-3052334	Inhibition of cholesterol synthesis in rat L6 cells Inhibition of cholesterol synthesis in rat L6 cells	[PMID: 18072721]

体内実験

PF-3052334 (10 mg/kg, p.o., single dose) PF-3052334 significantly inhibits cholesterol synthesis at both 2-4 h and 4-6 h in hamsters^[1].
PF-3052334 (20 mg/kg, p.o., once daily for 7 days) causes low density lipoprotein (LDL) reduction in guinea pigs with an ED₅₀ of 3.6 mg/kg^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Acute cholesterol synthesis inhibition model established in Male Syrian hamster (Golden hamster)^[1]
Dosage:

10 mg/kg
Administration:

Oral administration (p.o.), single dose
Result:

Significantly inhibited cholesterol synthesis at both 2-4 h and 4-6 h.

Animal Model:

Chronic LDL-C reduction experiment established in male Hartley guinea pig^[1]
Dosage:

20 mg/kg
Administration:

Oral administration (p.o.), once daily for 7 days
Result:

Reduced LDL-C by 45%

化学情報

CAS 番号 887702-61-6
分子量 533.57
分子式 C₂₈H₃₃FN₃NaO₅
SMILES

O=C(O[Na])C[C@H](O)C[C@H](O)CCC1=C(C(C)C)C(C(NCC2=CC=C(C=C2)C)=O)=NN1C3=CC=C(C=C3)F
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

Please store the product under the recommended conditions in the Certificate of Analysis.

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (271 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Pfefferkorn JA, et al. Substituted Pyrazoles as Hepatoselective HMG-CoA Reductase Inhibitors: Discovery of (3 R, 5 R)-7-[2-(4-Fluoro-phenyl)-4-isopropyl-5-(4-methyl-benzylcarbamoyl)-2 H-pyrazol-3-yl]-3, 5-dihydroxyheptanoic Acid (PF-3052334) as a Candidate for the Treatment of Hypercholesterolemia. Journal of medicinal chemistry. 2008 Jan 10;51(1):31-45.

Calculators

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

お問い合わせ在庫あり

Other size

お問い合わせ